Tuesday, November 12, 2013, 1:30 p.m. - 2:25 p.m., Room 405
The prevalence of cancer, diabetes and cardiovascular diseases continue to rise in China, primarily due to a growing aging population and urbanization. To what extent are current standards of care falling short, and what novel products and technologies are around the corner to fill the void? Hear leading experts discuss these questions, and learn how the industry is addressing unmet medical needs to improve healthcare in China.
- Nick Zhang, PhD, China General Manager, Senior Vice President, Frontage Lab
- Friedhelm Blobel, PhD, President & CEO, SciClone Pharmaceuticals
- Bruno Osterwalder, MD, Senior VP, Senior Strategic Advisor Oncology, Global Drug Development and Medical, Merck Serono
- Grace Xu, VP, Product Development & Strategic Planning, Bristol-Myers Squibb